Andrew Simon Bell

List of Publications by Year in Descending Order

46 papers	1,326 citations	18 h-index	36 g-index
50 ext. papers	1,459 ext. citations	3.7 avg, IF	3.78 L-index

#	Paper	IF	Citations
46	The discovery of a novel series of compounds with single-dose efficacy against juvenile and adult Schistosoma species. *PLoS Neglected Tropical Diseases*, **2021**, 15, e0009490	4.8	4
45	Novel Thienopyrimidine Inhibitors of -Myristoyltransferase with On-Target Activity in Intracellular Amastigotes. *Journal of Medicinal Chemistry*, **2020**, 63, 7740-7765	8.3	5
44	Structure-Guided Identification of Resistance Breaking Antimalarial N-Myristoyltransferase Inhibitors. *Cell Chemical Biology*, **2019**, 26, 991-1000.e7	8.2	15
43	Fragment-derived inhibitors of human N-myristoyltransferase block capsid assembly and replication of the common cold virus. *Nature Chemistry*, **2018**, 10, 599-606	17.6	53
42	Structure-guided optimization of quinoline inhibitors of -myristoyltransferase. *MedChemComm*, **2017**, 8, 191-197	5	8
41	Plate-based diversity subset screening generation 2: an improved paradigm for high-throughput screening of large compound files. *Molecular Diversity*, **2016**, 20, 789-803	3.1	4
40	High Throughput Screening Identifies Novel Lead Compounds with Activity against Larval, Juvenile and Adult Schistosoma mansoni. *PLoS Neglected Tropical Diseases*, **2016**, 10, e0004659	4.8	30
39	Diverse modes of binding in structures of Leishmania major N-myristoyltransferase with selective inhibitors. *IUCrJ*, **2014**, 1, 250-60	4.7	27
38	Structure-based design of potent and selective Leishmania N-myristoyltransferase inhibitors. *Journal of Medicinal Chemistry*, **2014**, 57, 8664-70	8.3	44
37	Crystal Structures of Phosphodiesterase 9A and Insight into Inhibitor Discovery. *Methods and Principles in Medicinal Chemistry*, **2014**, 105-116	0.4	
36	The State of the Art in Selective PDE2A Inhibitor Design. *Methods and Principles in Medicinal Chemistry*, **2014**, 83-104	0.4	2
35	PDEs as CNS Targets: PDE9 Inhibitors for Cognitive Deficit Diseases. *Methods and Principles in Medicinal Chemistry*, **2014**, 117-140	0.4	1
34	PDE4: Recent Medicinal Chemistry Strategies to Mitigate Adverse Effects. *Methods and Principles in Medicinal Chemistry*, **2014**, 45-64	0.4	2
33	The Function, Enzyme Kinetics, Structural Biology, and Medicinal Chemistry of PDE10A. *Methods and Principles in Medicinal Chemistry*, **2014**, 65-82	0.4	1
32	Toward a New Generation of PDE5 Inhibitors through Advances in Medicinal Chemistry. *Methods and Principles in Medicinal Chemistry*, **2014**, 9-28	0.4	
31	PDE4: New Structural Insights into the Regulatory Mechanism and Implications for the Design of Selective Inhibitors. *Methods and Principles in Medicinal Chemistry*, **2014**, 29-44	0.4	1
30	Phosphodiesterase 8B. *Methods and Principles in Medicinal Chemistry*, **2014**, 141-154	0.4	

29	Selective New Small-Molecule Inhibitors of Phosphodiesterase 1. *Methods and Principles in Medicinal Chemistry*, **2014**, 155-164	0.4	3
28	Recent Advances in the Development of PDE7 Inhibitors. *Methods and Principles in Medicinal Chemistry*, **2014**, 165-190	0.4	
27	Inhibitors of Protozoan Phosphodiesterases as Potential Therapeutic Approaches for Tropical Diseases. *Methods and Principles in Medicinal Chemistry*, **2014**, 191-210	0.4	1
26	Using a non-image-based medium-throughput assay for screening compounds targeting N-myristoylation in intracellular Leishmania amastigotes. *PLoS Neglected Tropical Diseases*, **2014**, 8, e3363	4.8	15
25	N-Myristoyltransferase as a potential drug target in malaria and leishmaniasis. *Parasitology*, **2014**, 141, 37-49	2.7	55
24	TAK1 inhibition in the DFG-out conformation. *Chemical Biology and Drug Design*, **2013**, 82, 500-5	2.9	14
23	Plate-based diversity subset screening: an efficient paradigm for high throughput screening of a large screening file. *Molecular Diversity*, **2013**, 17, 319-35	3.1	7
22	Shaping a screening file for maximal lead discovery efficiency and effectiveness: elimination of molecular redundancy. *Journal of Chemical Information and Modeling*, **2012**, 52, 2937-49	6.1	35
21	Selective inhibitors of protozoan protein N-myristoyltransferases as starting points for tropical disease medicinal chemistry programs. *PLoS Neglected Tropical Diseases*, **2012**, 6, e1625	4.8	58
20	Discovery of a series of potent and selective human H4 antagonists using ligand efficiency and libraries to explore structure-activity relationship (SAR). *Bioorganic and Medicinal Chemistry Letters*, **2011**, 21, 6591-5	2.9	5
19	Challenges of drug discovery in novel target space. The discovery and evaluation of PF-3893787: a novel histamine H4 receptor antagonist. *Bioorganic and Medicinal Chemistry Letters*, **2011**, 21, 6596-602	2.9	26
18	Novel phosphodiesterase type 5 modulators: a patent survey (2008 - 2010). *Expert Opinion on Therapeutic Patents*, **2011**, 21, 1631-41	6.8	19
17	The discovery of potent, selective, and orally bioavailable PDE9 inhibitors as potential hypoglycemic agents. *Bioorganic and Medicinal Chemistry Letters*, **2009**, 19, 2537-41	2.9	39
16	Identification, synthesis and SAR of amino substituted pyrido[3,2b]pyrazinones as potent and selective PDE5 inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2009**, 19, 4088-91	2.9	21
15	Searching chemical space with the Bayesian Idea Generator. *Journal of Chemical Information and Modeling*, **2009**, 49, 2211-20	6.1	10
14	Design of second generation phosphodiesterase 5 inhibitors. *Current Topics in Medicinal Chemistry*, **2007**, 7, 405-19	3	46
13	Synthesis of 1,2-disubstituted-3-alkylidenylpyrrolidines via a one-pot three-component reaction. *Tetrahedron Letters*, **2004**, 45, 8511-8514	2	12
12	Facile palladium catalysed functionalisation of 1,2-isothiazoline-3-ones and the highly diastereoselective Diels-Alder reactions of 4-vinyl-1,2-isothiazoline-3-one-1-oxides. *Tetrahedron*, **1999**, 55, 12313-12330	2.4	10

11	Generation and cycloadditions of 2-(N-acylamino)-1-thia-1,3-dienes part III: Control of diastereoselectivity using homochiral auxiliaries. *Tetrahedron*, **1998**, 54, 3219-3234	2.4	18
10	Novel antifungal 2-aryl-1-(1H-1,2,4-triazol-1-yl)butan-2-ol derivatives with high activity against Aspergillus fumigatus. *Bioorganic and Medicinal Chemistry Letters*, **1996**, 6, 2031-2036	2.9	78
9	Highly efficient diastereoselective Exo Diels-Alder reactions of homochiral 2-(N-acylamino)-1-thia-1,3-dienes: A powerful entry into optically pure thiopyrans. *Tetrahedron Letters*, **1996**, 37, 123-126	2	18
8	Sildenafil (VIAGRATM), a potent and selective inhibitor of type 5 cGMP phosphodiesterase with utility for the treatment of male erectile dysfunction. *Bioorganic and Medicinal Chemistry Letters*, **1996**, 6, 1819-1824	2.9	517
7	Remarkably high diastereoselective exo diels-alder reactivity of 4-vinyl isothiazoline-3-one-1-oxides: The sulphoxide Syn effect.. *Tetrahedron Letters*, **1995**, 36, 7713-7716	2	5
6	Facile palladium catalysed functionalisation of 1,2-isothiazoline-3-ones. *Tetrahedron Letters*, **1994**, 35, 6551-6554	2	14
5	2(1H)-quinolinones with cardiac stimulant activity. 3. Synthesis and biological properties of 6-imidazol-1-yl derivatives. *Journal of Medicinal Chemistry*, **1989**, 32, 1552-8	8.3	11
4	7-Heteroaryl-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin -2(1H)-one derivatives with cardiac stimulant activity. *Journal of Medicinal Chemistry*, **1989**, 32, 2042-9	8.3	10
3	2(1H)-quinolinones with cardiac stimulant activity. 2. Synthesis and biological activities of 6-(N-linked, five-membered heteroaryl) derivatives. *Journal of Medicinal Chemistry*, **1989**, 32, 575-83	8.3	40
2	2(1H)-quinolinones with cardiac stimulant activity. 1. Synthesis and biological activities of (six-membered heteroaryl)-substituted derivatives. *Journal of Medicinal Chemistry*, **1988**, 31, 2048-56	8.3	40
1	Triazole Antifungals: Itraconazole (Sporanox), Fluconazole (Diflucan), Voriconazole (Vfend), and Fosfluconazole (Prodif)71-82		2